Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen And The Biosimilar Threat: Lessons From Affymax
Amgen And The Biosimilar Threat: Lessons From Affymax
Amgen And The Biosimilar Threat: Lessons From Affymax
Submitted by
admin
on March 8, 2013 - 11:12am
Source:
Seeking Alpha
News Tags:
biosimilars
Amgen
Affymax
AbbVie
Biogen Idec
Celgene
Fresenius
Merck
Gilead
Headline:
Amgen And The Biosimilar Threat: Lessons From Affymax
Do Not Allow Advertisers to Use My Personal information
